| 000 | 04805nam a22005055i 4500 | ||
|---|---|---|---|
| 001 | 978-1-60327-198-1 | ||
| 003 | DE-He213 | ||
| 005 | 20260610083703.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 101130s2011 xxu| s |||| 0|eng d | ||
| 020 |
_a9781603271981 _9978-1-60327-198-1 |
||
| 024 | 7 |
_a10.1007/978-1-60327-198-1 _2doi |
|
| 050 | 4 | _aTP248.13-248.65 | |
| 072 | 7 |
_aTCB _2bicssc |
|
| 072 | 7 |
_aSCI010000 _2bisacsh |
|
| 072 | 7 |
_aTCB _2thema |
|
| 082 | 0 | 4 |
_a660.6 _223 |
| 245 | 1 | 0 |
_aCharacterization of Nanoparticles Intended for Drug Delivery _h[electronic resource] / _cedited by Scott E. McNeil. |
| 250 | _a1st ed. 2011. | ||
| 264 | 1 |
_aTotowa, NJ : _bHumana Press : _bImprint: Humana, _c2011. |
|
| 300 |
_aXII, 269 p. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 |
_aMethods in Molecular Biology, _x1940-6029 ; _v697 |
|
| 505 | 0 | _aUnique Benefits of Nanotechnology to Drug Delivery and Diagnostics -- Challenges for Nanoparticle Characterization -- Considerations when submitting nano-therapeutics to FDA/CDER for regulatory review -- Measuring the Hydrodynamic Size of Nanoparticles in Aqueous Media Using Batch-Mode Dynamic Light Scattering -- Characterization of Nanoparticles by Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry -- Zeta Potential Measurement -- Size Measurement of Nanoparticles using Atomic Force Microscopy -- Biological Tissue and Cell Culture Specimen Preparation for TEM Nanoparticle Characterization.– SEM X-ray Microanalysis of Nanoparticles Present in Tissue or Cultured Cell Thin Sections -- Detecting and Measuring Free Gadolinium in Nanoparticles for MRI Imaging -- Lipid Component Quantitation by Thin Layer Chromatography -- Detection and Quantitative Evaluation of Endotoxin Contamination in Nanoparticle Formulations by LAL-based Assays -- Analysis of microbial contamination in nanoparticle formulations -- Gold Nanoparticle Quantitation via Fluorescence in Solution and Cell Culture -- Quantitation of Nanoparticles in Serum Matrix by Capillary Electrophoresis -- Evaluation of Cytotoxicity of Nanoparticulate Materials in Porcine Kidney Cells and Human Hepatocarcinoma Cells -- Monitoring Nanoparticle-Treated Hepatacarcinoma Cells for Apoptosis – Detecting Reactive Oxygen Species in Primary Hepatocytes Treated with Nanoparticles -- Assay to Detect Lipid Peroxidation Upon Exposure to Nanoparticles -- Monitoring Glutathione Homeostasis in Nanoparticle-Treated Hepatocytes -- Autophagy Monitoring Assay: Qualitative Analysis of MAP LC3-I to II Conversion by Immunoblot -- Monitoring Lysosomal Activity in Nanoparticle-Treated Cells -- Method for Analysis of Nanoparticle Hemolytic Properties in Vitro -- Method for In Vitro Analysis of Nanoparticle Thrombogenic Properties -- Qualitative Analysis of Total Complement Activation by Nanoparticles -- Method for Analysis ofNanoparticle Effects on Cellular Chemotaxis -- In Vitro Analysis of Nanoparticle Uptake by Macrophages Using Chemiliuminescence. | |
| 520 | _aIn recent years, there have been many exciting breakthroughs in the application of nanotechnology to medicine. In Characterization of Nanoparticles Intended for Drug Delivery, expert researchers explore the latest advances in the field, providing a set of basic methods for the characterization of nanomaterials for medical use. Chapters provide methods to characterize the physiochemical properties (size, aggregation, and surface chemistry) and in vitro immunological and biological characteristics of nanomaterials. Composed in the highly successful Methods in Molecular Biology™ series format, each chapter contains a brief introduction, step-by-step methods, a list of necessary materials, and a Notes section which shares tips on troubleshooting and avoiding known pitfalls. Comprehensive and informative, Characterization of Nanoparticles Intended for Drug Delivery is an essential survey of methods that are crucial to the preclinical characterization of nanomedicines. | ||
| 650 | 0 | _aBiotechnology. | |
| 650 | 0 | _aNanotechnology. | |
| 650 | 0 | _aPharmacy. | |
| 650 | 1 | 4 | _aBiotechnology. |
| 650 | 2 | 4 | _aNanotechnology. |
| 650 | 2 | 4 | _aPharmacy. |
| 700 | 1 |
_aMcNeil, Scott E. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer Nature eBook | |
| 776 | 0 | 8 |
_iPrinted edition: _z9781603271974 |
| 776 | 0 | 8 |
_iPrinted edition: _z9781607619086 |
| 776 | 0 | 8 |
_iPrinted edition: _z9781493961139 |
| 830 | 0 |
_aMethods in Molecular Biology, _x1940-6029 ; _v697 |
|
| 856 | 4 | 0 | _uhttps://doi.org/10.1007/978-1-60327-198-1 |
| 912 | _aZDB-2-PRO | ||
| 999 |
_c7389 _d7389 |
||